Late toxicity of image-guided hypofractionated radiotherapy for prostate: non-randomized comparison with conventional fractionation
- PMID: 30219945
- DOI: 10.1007/s11547-018-0937-9
Late toxicity of image-guided hypofractionated radiotherapy for prostate: non-randomized comparison with conventional fractionation
Erratum in
-
Correction to: Late toxicity of image-guided hypofractionated radiotherapy for prostate: non-randomized comparison with conventional fractionation.Radiol Med. 2020 Jan;125(1):107. doi: 10.1007/s11547-019-01086-w. Radiol Med. 2020. PMID: 31591702
Abstract
Purpose: To evaluate the incidence and predictors for late toxicity and tumor outcome after hypofractionated radiotherapy using three different image-guided radiotherapy (IGRT) systems (hypo-IGRT) compared with conventional fractionation without image guidance (non-IGRT).
Methods and materials: We compared the late rectal and urinary toxicity and outcome in 179 prostate cancer patients treated with hypo-IGRT (70.2 Gy/26 fractions) and 174 non-IGRT patients (80 Gy/40 fractions). Multivariate analysis was performed to define predictors for late toxicity. 5- and 8-year recurrence-free survival (RFS) and overall survival (OS) were analyzed.
Results: Mean follow-up was 81 months for hypo-IGRT and 90 months for non-IGRT group. Mainly mild late toxicity was observed: Hypo-IGRT group experienced 65 rectal (30.9% G1/G2; 6.3% G3/G4) and 105 urinary events (56% G1/G2; 4% G3/G4). 5- and 8-year RFS rates were 87.5% and 86.8% (hypo-IGRT) versus 80.4% and 66.8% (non-IGRT). 5- and 8-year OS rates were 91.3% and 82.7% in hypo-IGRT and 92.2% and 84% in non-IGRT group. Multivariate analysis showed that hypo-IGRT is a predictor for late genitourinary toxicity, whereas hypo-IGRT, acute urinary toxicity and androgen deprivation therapy are predictors for late rectal toxicity. Advanced T stage and higher Gleason score (GS) were correlated with worse RFS.
Conclusions: A small increase in mild late toxicity, but not statistically significant increase in severe late toxicity in the hypo-IGRT group when compared with conventional non-IGRT group was observed. Our study confirmed that IGRT allows for safe moderate hypofractionation, offering a shorter overall treatment time, a good impact in terms of RFS and providing potentially more economic health care.
Keywords: Conventional fractionation; Hypofractionation; Image-guided radiotherapy; Late toxicity; Prostate cancer.
Similar articles
-
Acute toxicity of image-guided hypofractionated radiotherapy for prostate cancer: nonrandomized comparison with conventional fractionation.Urol Oncol. 2011 Sep-Oct;29(5):523-32. doi: 10.1016/j.urolonc.2009.10.004. Epub 2009 Dec 16. Urol Oncol. 2011. PMID: 20005749
-
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.Lancet. 2019 Aug 3;394(10196):385-395. doi: 10.1016/S0140-6736(19)31131-6. Epub 2019 Jun 18. Lancet. 2019. PMID: 31227373 Clinical Trial.
-
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.Lancet Oncol. 2021 Feb;22(2):235-245. doi: 10.1016/S1470-2045(20)30581-7. Epub 2021 Jan 11. Lancet Oncol. 2021. PMID: 33444529 Clinical Trial.
-
Pelvic Complications After Prostate Cancer Radiation Therapy and Their Management: An International Collaborative Narrative Review.Eur Urol. 2019 Mar;75(3):464-476. doi: 10.1016/j.eururo.2018.12.003. Epub 2018 Dec 17. Eur Urol. 2019. PMID: 30573316
-
Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy.Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1297-308. doi: 10.1016/j.ijrobp.2004.12.052. Int J Radiat Oncol Biol Phys. 2005. PMID: 16029785 Review.
Cited by
-
Early results of PRO-EPI: PROspective multicenter observational study on elective pelvic nodes irradiation in patients with intermediate/high/very high-risk non-metastatic prostate cancer submitted to radical, adjuvant, or salvage radiotherapy with or without concomitant androgen deprivation therapy.Front Oncol. 2022 Nov 2;12:951220. doi: 10.3389/fonc.2022.951220. eCollection 2022. Front Oncol. 2022. PMID: 36408148 Free PMC article.
-
Influence of demographic change on the demand for radiotherapy using forecasted predictions for prostate cancer in Germany.Strahlenther Onkol. 2024 Aug;200(8):671-675. doi: 10.1007/s00066-023-02133-2. Epub 2023 Aug 28. Strahlenther Onkol. 2024. PMID: 37638976 Free PMC article.
-
Multiparametric MRI in the management of prostate cancer: an update-a narrative review.Gland Surg. 2020 Dec;9(6):2321-2330. doi: 10.21037/gs-20-561. Gland Surg. 2020. PMID: 33447583 Free PMC article. Review.
-
Impact of prostate position-based image-guidance in intensity-modulated radiation therapy for localized prostate cancer.Int J Clin Oncol. 2024 Mar;29(3):325-332. doi: 10.1007/s10147-023-02456-1. Epub 2024 Jan 8. Int J Clin Oncol. 2024. PMID: 38191958
-
The role of image-guided radiotherapy in prostate cancer: A systematic review and meta-analysis.Clin Transl Radiat Oncol. 2022 Nov 8;38:81-89. doi: 10.1016/j.ctro.2022.11.001. eCollection 2023 Jan. Clin Transl Radiat Oncol. 2022. PMID: 36407489 Free PMC article. Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical